WO2002060867A3 - Carbazole derivatives and their uses as heparanase inhibitors - Google Patents

Carbazole derivatives and their uses as heparanase inhibitors Download PDF

Info

Publication number
WO2002060867A3
WO2002060867A3 PCT/IL2002/000079 IL0200079W WO02060867A3 WO 2002060867 A3 WO2002060867 A3 WO 2002060867A3 IL 0200079 W IL0200079 W IL 0200079W WO 02060867 A3 WO02060867 A3 WO 02060867A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
carbazole derivatives
heparanase inhibitors
group
heparanase
Prior art date
Application number
PCT/IL2002/000079
Other languages
French (fr)
Other versions
WO2002060867A2 (en
Inventor
Maty Ayal-Hershkovitz
Daphna Miron
Avi Koller
Neta Ilan
Ofra Levy
Original Assignee
Insight Strategy And Marketing
Maty Ayal-Hershkovitz
Daphna Miron
Avi Koller
Neta Ilan
Ofra Levy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy And Marketing, Maty Ayal-Hershkovitz, Daphna Miron, Avi Koller, Neta Ilan, Ofra Levy filed Critical Insight Strategy And Marketing
Priority to AU2002228316A priority Critical patent/AU2002228316A1/en
Publication of WO2002060867A2 publication Critical patent/WO2002060867A2/en
Publication of WO2002060867A3 publication Critical patent/WO2002060867A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Carbazole derivatives having at the 9-position a 3-(substituted)amino-2-hydroxypropyl group and fluorene derivatives having at the 9-position a =N-NH-R4 group, wherein R4 is a (substituted) carboxamido, (substituted) thiocarboxamido or (substituted) hydrazido group, are provided as heparanase inhibitors suitable for the treatment of diseases and disorders caused by or associated with heparanase catalytic activity such as cancer, inflammatory disorders and autoimmune diseases.
PCT/IL2002/000079 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors WO2002060867A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002228316A AU2002228316A1 (en) 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26430401P 2001-01-29 2001-01-29
US60/264,304 2001-01-29

Publications (2)

Publication Number Publication Date
WO2002060867A2 WO2002060867A2 (en) 2002-08-08
WO2002060867A3 true WO2002060867A3 (en) 2004-03-18

Family

ID=23005445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000079 WO2002060867A2 (en) 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors

Country Status (2)

Country Link
AU (1) AU2002228316A1 (en)
WO (1) WO2002060867A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220214D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
EP1554262B1 (en) 2002-10-23 2007-12-05 Glenmark Pharmaceuticals Limited Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ATE427308T1 (en) * 2003-04-11 2009-04-15 Glenmark Pharmaceuticals Sa NEW HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES: METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
DE602004011400T2 (en) * 2004-01-29 2009-01-22 Cellzome Ag TREATMENT OF NEURODEEGENERATIVE DISEASES WITH GPR49
CA2555313A1 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US20060003966A1 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
JP2009519206A (en) 2004-10-13 2009-05-14 グレンマーク・ファーマシューティカルズ・エスエー Process for producing N- (3,5-dichloropyridin-4-yl) -4-difluoromethoxy-8-methanesulfonamido-dibenzo [B, D] furan-1-carboxamide
BRPI0517211B8 (en) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa compound, pharmaceutical composition and its use.
US7943634B2 (en) 2004-12-17 2011-05-17 Glenmark Pharmaceuticals S.A. Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors
EP1893192A4 (en) * 2005-06-08 2010-03-31 Univ North Carolina Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
AU2007312880A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
CA2734225A1 (en) * 2008-08-15 2010-02-18 Georgetown University Fluorescent regulators of rassf1a expression and human cancer cell proliferation
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) * 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
DK2590647T3 (en) 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
EP2925129A4 (en) * 2012-08-24 2016-06-08 Univ Texas Pro-neurogenic compounds
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2013372386B2 (en) 2013-01-10 2018-04-19 Merck Patent Gmbh Piperidinylcarbazole as antimalarial
JP2016516044A (en) 2013-03-15 2016-06-02 ファーマトロフィックス， インコーポレイテッド Non-peptide BDNF neurotrophin mimetic compound
WO2014143985A1 (en) 2013-03-15 2014-09-18 Pharmatrophix, Inc. Non-peptide bdnf neurotrophin mimetics
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
JP2017519795A (en) 2014-07-04 2017-07-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Azepanyl derivatives having antiparasitic activity and pharmaceutical compositions containing the same
CA2959624A1 (en) * 2014-09-02 2016-03-10 The Children's Hospital Of Philadelphia Compositions and methods for the inhibition of chondrogenesis
ES2899852T3 (en) 2014-12-17 2022-03-15 Pimco 2664 Ltd N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(-4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
KR101652305B1 (en) * 2015-02-02 2016-08-30 충남대학교산학협력단 Composition containing the carbazole urea derivative for preventing or treating vascular disease
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
US11053255B2 (en) 2015-06-22 2021-07-06 Georgetown University Synthesis of mahanine and related compounds
CA3046997A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381906A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Compounds for use as heparanase inhibitors
CN111217741B (en) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Fluorine-substituted monocarbazole derivative, preparation method and application thereof
CN117486782A (en) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 N-substituted carbazole derivative and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407940A (en) * 1992-10-02 1995-04-18 Adir Et Compagnie New ellipticine compounds
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents
US5407940A (en) * 1992-10-02 1995-04-18 Adir Et Compagnie New ellipticine compounds

Also Published As

Publication number Publication date
WO2002060867A2 (en) 2002-08-08
AU2002228316A1 (en) 2002-08-12

Similar Documents

Publication Publication Date Title
WO2002060867A3 (en) Carbazole derivatives and their uses as heparanase inhibitors
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
AU2003268156A1 (en) Novel pyrazolopyridine derivatves as pharmaceutical agents
NO20012977L (en) N-ureidoalkylpiperidines as modulators of chemokine receptor activity
WO2004009017A3 (en) Modulators of the glucocorticoid receptor and method
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
YU69902A (en) New piperazine derivatives
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
NO20053384D0 (en) Benzazepine derivatives for the treatment of neurological disorders.
HK1046413B (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
WO2003005960A3 (en) Novel bicyclic and tricyclic cannabinoids
WO2001098279A3 (en) Bis-arylsulfones
WO2001028987A8 (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
WO2005053609A3 (en) Methods of nad+-dependent deacetylase inhibitors
HK1029942A1 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma.
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2002060375A3 (en) Diphenyl ether derivatives and their uses as heparanase inhibitors
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP